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Supplementary Tables and Figures
The genetic instrument for the exposure, subjective wellbeing, was 3 genome-wide significant SNPs that each explain 0.1% of the variance, identified by the SSGAC [1] . Due to a restricted number of SNPs, MR-Egger, MBE and MR-PRESSO could not be conducted. One unit increase of subjective wellbeing is equivalent to one standard deviation increase of the subjective wellbeing composite continuous scale. The genetic instrument was the 3 genome-wide significant SNPs for subjective wellbeing from Okbay et al [1] . Suitable proxies were identified at an LD cut-off R 2 >0.8. Arrows on confidence intervals indicate they extend beyond the axis. Phenotype scores for all measures were standardised apart from for blood pressure which is represented on a different scale. There was no clear evidence to suggest a causal effect of subjective wellbeing on any of the health outcomes (see Figure 2 ). . Leave-one-out analysis: each row represents a two-sample MR analysis of BMI on subjective wellbeing using all of the genome-wide significant SNPs available from Locke et al. [2] except for the SNP listed on the y-axis. The point represents the effect size with that SNP removed and the line represents the standard error.
Leave-one-out analysis was conducted using MR Base [3] to identify if any individual SNPs were driving the association between BMI and wellbeing. Results are shown in Figure S2 . The SNP with the largest contribution to the effect is rs1421085 located on chromosome 16 in the second intron of the FTO (fat mass and obesity associated) gene. FTO has been repeatedly associated with obesity in different populations [4] . However, the biological consequences of intronic FTO SNPs are still unknown. They are currently thought to play a regulatory role in FTO gene expression in the hypothalamus [5] .
Although research is not completely certain of the role of FTO, its large effect size and robust association with obesity suggest that this gene has the largest effect in the twosample MR because of its BMI effect size rather than because of pleiotropic effects. Figure S4 . Bias plots of association with baseline confounders for BMI, comparing observational and MR analyses Willer [7] 2013 GLGC 4%
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Criteria for defining cases is given separately for each cohort in the cohort descriptions supplementary note [6] . Of the CAD cases, ~70% had a reported history of MI.
Given for each cohort in the cohort descriptions supplementary note [6] .
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Total Cholesterol Where possible, individuals on lipid lowering medication were excluded. The majority of studies measured lipids after >8 hours of fasting. 24% of studies directly measured cholesterol and the rest estimated it using the Friedewald formula. Total cholesterol is calculated from HDL, LDL and triglycerides. [12] . None is associated with MDD in the current GWAS at the genome-wide level of significance. A1 = effect allele, A2 = non-effect allele, EAF = effect allele frequency. rG between subjective wellbeing and MDD was -0.65 (SE = 0.04) [12] . Regression dilution bias occurs when the SNPs are weakly associated with the exposure. This is also known as the `NO Measurement Error' (NOME) assumption. The I 2 statistic for the SNP-exposure (GX) effects is a measure of NOME violation. In order to conduct MR Egger regression I 2 should be greater than 0.9 or else simulation extrapolation (SIMEX) correction should be applied [13] . Note: df = degrees of freedom where degrees of freedom is equal to the number of SNPs -1. Q = Cochran's Q, a test of heterogeneity or dispersion in the SNP effects. Separate clusters of SNP effects suggest that they are acting through different pathways. This is an indicator that there might be a pleiotropic pathway. Figure 3 . Only the exposures BMI, waist circumference and HDL cholesterol had significant global tests and outlier tests. 
